Latest News

Aagami has received contract extension from California client for partnering of their first in class eye drop to reverse cataract non-invasively

Our clients’ affinity for us continues to grow. Aagami has received another contract extension. The client is developing small molecule eye dro...

Published : 22 Mar 2026

Read More

New Assignment: Outlicensing and Distribution rights for Marketed Dental gel addressing Periodontitis, Gingivitis, & Caries

Aagami has received a new assignment from an existing client, to support regional/global partnering initiative for their Marketed Dental gel...

Published : 20 Mar 2026

Read More

New Assignment: Out-Licensing FDA validated Ionic Liquid Novel delivery platform (Transdermal and Oral) for complex modalities and overcoming API challenges regarding solubility, absorption, and metabolic effects

Aagami has received a new assignment from their publicly listed Japanese client, to establish R&D collaborations/Licensing partnerships for their&...

Published : 16 Mar 2026

Read More

Contract extension to provide strategic support related to IP sale of distressed clinical stage NCE

Aagami has received contract extension to provide strategic support related to IP sale of distressed clinical stage NCE. A first-in-class no...

Published : 18 Feb 2026

Read More

New Client Win: US company addressing unmet medical needs in CNS, Cardio, Metabolic, and Inflammatory diseases

After a productive JPM week including Biotech Showcase in San Francisco, Aagami has won its first new client of 2026, within few days. Client is ...

Published : 21 Jan 2026

Read More

Japanese client with FDA approved lidocaine patch has awarded contract extension to Aagami

Aagami has secured a contract extension from its publicly listed Japanese client to support US partnering for their patented, FDA-approved topical lid...

Published : 04 Dec 2025

Read More

Aagami Secures Contract Extension from US Client to Develop Phase 3 EPO Asset for Sudden Cardiac Arrest Resuscitation

Aagami has been granted a contract extension by its US-based client, who is working on a Phase 3 EPO asset designed to aid in resuscitation following ...

Published : 26 Nov 2025

Read More

New Client Win: Australian Pharma with Marketed Povidone-Iodine Antiseptic Nasal Spray

An innovative ASX-Listed Pharma from Australia, with Marketed Povidone-Iodine Antiseptic Nasal Spray has appointed Aagami to help out-license the...

Published : 20 Oct 2025

Read More

Aagami partnering calendar for 2026

We are pleased to announce that Aagami calendar of 2026 Partnering events is tentatively finalized.  Various members of Aagami are expected ...

Published : 11 Sep 2025

Read More

New Out-Licensing Assignment from Belgian client: with antibiotic-free selection technology in E. coli. Increased Yield, genetic stability and easy to use.

Aagami met its past Belgian client during BIO 2025 in Boston. Thereafter, now we have received a new out-licensing assignment from Belgian client.&nbs...

Published : 01 Aug 2025

Read More